ABIM Tx Hepatology common mistakes
ABIM Tx Hepatology · Understand the traps and how to avoid them.
Calculates the listing MELD with the retired MELD-Na formula, or uses a memory-based estimate that drops the albumin and sex coefficients.
MELD 3.0 replaced MELD-Na for UNOS allocation; many candidates trained on the older score and rely on rough recall under time pressure, and the sodium cap and creatinine floor are easy to misapply.
What to do instead
Use the UNOS MELD 3.0 calculator for every listing and re-certification decision, and be able to write the formula: 1.33(sex) + 4.56 ln bilirubin + 0.82 ln INR − 0.24 ln albumin + 9.53, plus 1.59 creatinine (floor 1.0, cap 4.0) and 1.32 sodium (cap 125–137).
Denies transplant to every patient with alcohol-associated liver disease who reports drinking within the past 6 months, without a structured psychosocial assessment.
The '6-month rule' is taught as policy even though UNOS does not mandate a fixed abstinence period; candidates conflate center practice with allocation policy and overestimate relapse risk.
What to do instead
Use a standardized assessment (SIPAT, AUDIT-C, DSM-5 severity), document insight and social support, and know that selected patients with shorter abstinence can be listed. Distinguish alcohol-associated hepatitis (usually a contraindication outside trials) from compensated alcohol-associated cirrhosis.
Orders fresh frozen plasma for an INR of 1.6–2.0 in a stable postoperative patient who is not bleeding.
The INR is treated as a bleeding-risk number, but the injured or cirrhotic liver synthesizes both pro- and anticoagulant factors; FFP adds volume and can cause TACO, pulmonary edema, and portal vein thrombosis.
What to do instead
Treat bleeding, not the INR. Use fibrinogen, platelet count, and TEG/ROTEM to guide products; reserve FFP for active bleeding or an urgent procedure. Accept an INR up to about 2.0 in a stable patient without bleeding.
Attributes a day-7 bilirubin of 12 mg/dL, INR 1.8, and AST of 3000 U/L to expected preservation injury and delays Doppler ultrasound until the next day.
Early allograft dysfunction is common and often self-limited, so a true hepatic artery thrombosis or outflow obstruction is missed; the EAD criteria are not recalled.
What to do instead
Know EAD criteria (AST/ALT >2000, bilirubin ≥10 mg/dL, INR ≥1.6 on day 7) and that EAD is a diagnosis of exclusion. Obtain Doppler immediately for any graft dysfunction; evaluate hepatic artery, portal vein, and hepatic veins.
Diagnoses acute cellular rejection from a rise in transaminases and empirically increases tacrolimus without a biopsy or Banff scoring.
Rejection mimics recurrent disease, ischemia, drug injury, and infection; candidates underuse the Banff triad (mixed portal infiltrate, bile duct damage, venulitis) and the RAI score.
What to do instead
Biopsy before treating, score with the Banff RAI (0–9), and require at least two of the three features. Send C4d and DSA if antibody-mediated rejection is possible. Treat proven moderate or severe rejection with pulse steroids rather than blind escalation.
Keeps tacrolimus troughs at 10–12 ng/mL at 6 months post-transplant in a patient with rising creatinine and tremor.
Trough targets are memorized as one number, ignoring time post-transplant and the dose-related nephrotoxicity and neurotoxicity of calcineurin inhibitors.
What to do instead
Use time-stratified targets (e.g., 8–10 ng/mL early, 5–8 by 3–6 months in stable patients) and taper when toxicity appears. Recognize PRES and CNI nephrotoxicity, and consider switching to belatacept or an mTOR inhibitor.
Dilates every biliary stricture endoscopically without obtaining hepatic artery imaging.
Anastomotic strictures are common and benign, but nonanastomotic or diffuse intrahepatic stricturing suggests hepatic artery thrombosis or ischemic cholangiopathy, which changes management and prognosis.
What to do instead
Classify strictures as anastomotic versus nonanastomotic and image the hepatic artery with Doppler or CT angiography before assuming a benign cause. Diffuse nonanastomotic strictures may require retransplant evaluation.
Continues full-dose mycophenolate and tacrolimus in a patient with septic shock and acute kidney injury.
Fear of rejection outweighs the immediate mortality risk of infection; the principle that immunosuppression should be reduced in severe infection is not applied.
What to do instead
Reduce or hold the antimetabolite first, then lower the calcineurin inhibitor, while treating the infection. Do not stop all immunosuppression abruptly. Infection is a leading cause of early post-transplant death, and over-immunosuppression worsens it.
Assumes allograft dysfunction at 2 years is rejection and increases immunosuppression when the patient actually has recurrent primary biliary cholangitis or autoimmune hepatitis.
Recurrent disease is common and histologically overlaps with rejection; candidates underuse autoantibody testing and the distinctive histologic features.
What to do instead
Biopsy and test: AMA/IgM for recurrent PBC, IgG and autoantibodies for recurrent AIH, and cholangiography for recurrent PSC. Look for florid duct lesions, plasma cells, and interface hepatitis. Adjust immunosuppression only after the diagnosis is secure.
Does not screen for cardiovascular disease and de novo malignancy after transplant.
Attention stays on graft function and rejection, while metabolic syndrome and immunosuppression-driven cancers become the main late causes of death.
What to do instead
Screen annually for skin cancer and age-appropriately for colon, breast, and cervical cancer; manage hypertension, diabetes, and dyslipidemia; vaccinate; and recognize PTLD. Cardiovascular disease is a leading non-graft cause of late mortality.